ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2016
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Brain and behavior · 2026Pooled it
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.Journal for immunotherapy of cancer · 2019Pooled it
- Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.European journal of neurology · 2025Trial
- Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.European journal of neurology · 2024Trial
- Consistent improvement with eculizumab across muscle groups in myasthenia gravis.Annals of clinical and translational neurology · 2020Trial
- Article
- Review
- Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.Frontiers in immunology · 2026Article
- Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.JTO clinical and research reports · 2025Review
- Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan.Frontiers in neurology · 2025Article
- Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.Frontiers in immunology · 2025Article
- Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study.Journal of neurology, neurosurgery, and psychiatry · 2024Observational
- Defective autophagy and autophagy activators in myasthenia gravis: a rare entity and unusual scenario.Autophagy · 2024Review
- Mendelian randomization analyses of known and suspected risk factors and biomarkers for myasthenia gravis overall and by subtypes.BMC neurology · 2024Article
- Self-Reported Medication Adherence Measured with Morisky Scales in Rare Disease Patients: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2023Review
- Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.Neuropsychiatric disease and treatment · 2023Review
- Review
- The effect of pyridostigmine on post-stroke dysphagia: A randomized clinical trial.Current journal of neurology · 2022Article
- Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.Therapeutics and clinical risk management · 2022Review
- Nivolumab, a Double-Edged Sword: A Case Report of Nivolumab-Induced Myasthenia Gravis.Journal of medical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Myasthenia gravis (MG) is an autoimmune disease associated with the production of autoantibodies against 1) the skeletal muscle acetylcholine receptor; 2) muscle-specific kinase, a receptor tyrosine kinase critical for the maintenance of neuromuscular synapses; 3) low-density lipoprotein receptor-related protein 4, an important molecular binding partner for muscle-specific kinase; and 4) other muscle endplate proteins. In addition to the profile of autoantibodies, MG may be classified according the location of the affected muscles (ocular vs generalized), the age of symptom onset, and the nature of thymic pathology. Immunopathologic events leading to the production of autoantibodies differ in the various disease subtypes. Advances in our knowledge of the immunopathogenesis of the subtypes of MG will allow for directed utilization of the ever-growing repertoire of therapeutic agents that target distinct nodes in the immune pathway relevant to the initiation and maintenance of autoimmune disease. In this review, we examine the pathogenesis of MG subtypes, current treatment options, and emerging new treatments and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.